MAR 23, 2021 6:00 AM PDT

Assay Detects Antibodies in Asymptomatic COVID Carriers

WRITTEN BY: Tara Fernandez

It is estimated that around one in five people infected with SARS-CoV-2 will not show any infection symptoms. Some of these are pre-symptomatic, meaning that the COVID symptoms have yet to manifest, while others will remain completely asymptomatic throughout the course of infection. 

Despite not presenting with symptoms, these individuals still produce antibodies against the virus. However, commercially-available serology tests (assays that look for antibodies against specific viral proteins) often fail to catch these unique patient populations.

Now, a group of infectious disease researchers has developed a novel serology test with a wider “net”, capturing the full range of antibodies that the immune system produces against the viral spike protein. Additionally, the cell-based assay reveals the subclass of antibodies present in the circulation, which could provide insights into which stage of infection the patient is experiencing.

To develop the assay, the researchers used SARS-CoV-2’s spike protein gene. The spike protein acts like a key, latching on to receptors on human lung cells and gaining access to the cell’s interior. The scientists genetically modified cells to express the spike protein on their surface. They then incubated these cells with plasma samples from patients. Flow cytometry, a technique used to detect and measure cell characteristics, was used to determine the subclasses of antibodies against the spike protein present in the sample.

This flow cytometry-based method was found to pick up 97 percent of COVID infections in pre-symptomatic and asymptomatic individuals, even those who had minute amounts of antibodies against the virus in circulation. These results were a significant improvement over those obtained using commercially-available serology tests, which only identified around 30 percent of asymptomatic patients. The scientists found that IgG1 was the dominant IgG subclass present in both symptomatic and asymptomatic individuals.

As the assay uses the full-length gene for the spike protein, it will likely still be effective even amidst the emergence of new SARS-CoV-2 variants. This technique could help boost contract tracing efforts to contain the spread of the virus in the community. “This would greatly help to form better public policy decisions to manage and limit COVID-19 infection,” wrote the authors.

 

 

Source: Cell Reports Medicine.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 15, 2021
Immunology
Your Immune System Can't Deal With All the Plastic You're Eating
JUL 15, 2021
Your Immune System Can't Deal With All the Plastic You're Eating
Microplastics—tiny fragments of plastic, less than five millimeters in diameter—pollute our environment and, ...
AUG 18, 2021
Cannabis Sciences
Cannabis Use Disorder Linked to COVID Hospitalization
AUG 18, 2021
Cannabis Use Disorder Linked to COVID Hospitalization
People with a genetic predisposition to cannabis use disorder (CUD) are more likely to require hospitalization after con ...
AUG 23, 2021
Cancer
A Safe and Effective Combination Therapy for Advanced Cancer
AUG 23, 2021
A Safe and Effective Combination Therapy for Advanced Cancer
Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have m ...
SEP 08, 2021
Health & Medicine
Gene Linked to Endometriosis Could Lead to Non-Hormonal Treatment Options
SEP 08, 2021
Gene Linked to Endometriosis Could Lead to Non-Hormonal Treatment Options
Researchers from the University of Oxford found an association between neuropeptide S receptor 1 (NPSR1) gene variants a ...
SEP 26, 2021
Coronavirus
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
SEP 26, 2021
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
Humans can produce millions or even billions of antibodies, so only so many can be captured and screened. But those anti ...
SEP 27, 2021
Cell & Molecular Biology
Newly Identified Cell Type is Linked to Chronic Skin Disorders
SEP 27, 2021
Newly Identified Cell Type is Linked to Chronic Skin Disorders
The chronic skin disease atopic dermatitis (AD) is estimated to affect about 15 percent of children worldwide, and for s ...
Loading Comments...